| Basics |
Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals Inc is a biotechnology company which is focused on advancing innovative product opportunities in areas of large unmet needs such as constipation, gastrointestinal disorders, hyperuricemia, among others.
|
| IPO Date: |
February 3, 2010 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$510.81M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.23 | 2.15%
|
| Avg Daily Range (30 D): |
$0.11 | 5.34%
|
| Avg Daily Range (90 D): |
$0.07 | 4.85%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.27M |
| Avg Daily Volume (30 D): |
2.25M |
| Avg Daily Volume (90 D): |
1.46M |
| Trade Size |
| Avg Trade Size (Sh.): |
138 |
| Avg Trade Size (Sh.) (30 D): |
203 |
| Avg Trade Size (Sh.) (90 D): |
216 |
| Institutional Trades |
| Total Inst.Trades: |
7,515 |
| Avg Inst. Trade: |
$1.93M |
| Avg Inst. Trade (30 D): |
$.95M |
| Avg Inst. Trade (90 D): |
$1.21M |
| Avg Inst. Trade Volume: |
.18M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.59M |
| Avg Closing Trade (30 D): |
$.65M |
| Avg Closing Trade (90 D): |
$1.12M |
| Avg Closing Volume: |
251.89K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$.17
|
$.25
|
$.15
|
|
Diluted EPS
|
$.17
|
$.23
|
$.14
|
|
Revenue
|
$ 338.99M
|
$ 122.06M
|
$ 85.24M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ 28.55M
|
$ 40.08M
|
$ 23.6M
|
|
Operating Income / Loss
|
$ 123.19M
|
$ 75.48M
|
$ 45.32M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 52.86M
|
$ 47.58M
|
$ -14.98M
|
|
PE Ratio
|
18.47
|
|
|
|
|
|
